A New Cancer Vaccine Appears to Significantly Improve Survival in People in Remission From AML – MSK
David A. Scheinberg/mskcc.org

A New Cancer Vaccine Appears to Significantly Improve Survival in People in Remission From AML – MSK

Memorial Sloan Kettering Cancer Center shared on LinkedIn:

“A new cancer vaccine appears to significantly improve survival in people in remission from acute myeloid leukemia (AML), according to new results from a phase 3 clinical trial.

The vaccine, galinpepimut-S (GPS), is an ‘off-the-shelf’ vaccine invented by MSK leukemia specialist and physician-scientist Dr. David A. Scheinberg.

MSK

In the trial of 126 patients, it reduced the risk of death by 41%.

Median overall survival was 24.0 months with the vaccine compared with 14.7 months for patients on standard treatments.

The vaccine appeared safe, with minimal side effects.

‘These insights are helping lay the groundwork for these exciting, new immune-based approaches that could safely benefit more people with cancer. These data bring us closer to having the first off-the-shelf vaccine for AML patients.’ – says Dr. Scheinberg.

Learn more about the phase 3 results for this AML vaccine and what they could mean for people with acute myeloid leukemia: Vaccine Improves Survival in People with Acute Myeloid Leukemia (AML).”

You can also read: Acute Myeloid Leukemia: Genetic Origins May Trace Back Decades Before Diagnosis.

OncoDaily